The identification of biomarkers, such as SPRY2 and IL-1 from our upstream regulator analysis, can suggest mechanisms of tumor proliferation and approaches for adjuvant therapy, due to the potential of such proteins to become eventual targets for drug repositioning. The gene discussed is SPRY2; the disease is neoplasm.